[Form 4] Indaptus Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Aclaris Therapeutics (Nasdaq: ACRS) has filed a Form 8-K to inform investors that it will host a conference call on 29 Jul 2025 to review top-line data from its Phase 2a study of ATI-2138, an oral covalent ITK/JAK3 inhibitor for moderate-to-severe atopic dermatitis. Two items are furnished: Exhibit 99.1 (investor presentation) and Exhibit 99.2 (press release). Under Reg FD, Items 7.01 and 8.01 are furnished—not filed—so the information is not subject to Exchange Act liability nor automatically incorporated into other SEC reports.

The 8-K contains no numerical efficacy, safety, or financial metrics. Investors must consult the accompanying exhibits or join the conference call for detailed results. No changes to financial statements or previously issued guidance are included.

Positive

• Announcement of top-line Phase 2a results for ATI-2138 signals ongoing development progress and upcoming clinical visibility.

Negative

• Filing lacks any efficacy or safety data, leaving investors unable to gauge clinical success or valuation impact.

Insights

Biotech Analyst

TL;DR: Filing announces forthcoming Phase 2a data; impact indeterminate until actual numbers released.

Pipeline progress matters in biotech valuations, and ATI-2138’s emergence from Phase 2a is a gating event. However, the 8-K omits efficacy or safety readouts, preventing assessment of clinical or commercial viability. Investors should withhold judgment until Exhibit 99.2 is reviewed or management comments on response rates, pruritus scores and adverse events.

Securities Analyst

TL;DR: Procedural 8-K; no immediate valuation catalyst without data.

The filing satisfies Reg FD by alerting the market to an upcoming disclosure. Because the information is furnished, it does not trigger SEC liability or automatic inclusion in future filings. Absent quantitative results, share-price impact is likely muted until the press release or call provides clarity on trial success, timeline to Phase 3 and funding needs.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Meckler Jeffrey A

(Last) (First) (Middle)

C/O INDAPTUS THERAPEUTICS, INC

3 COLUMBUS CIRCLE, 15TH FLOOR

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Indaptus Therapeutics, Inc. [ INDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/27/2025		A		6,068(1)	A	$8.3024(1)	13,312	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Warrants	$8.3024	07/27/2025		A		12,136(1)		07/27/2025	07/27/2030	Common Stock	12,136	$8.3024(1)	16,688	D

Explanation of Responses:

1. The Reporting Person acquired 6,068 shares of common stock and 12,136 warrants to purchase common stock from the Issuer following the mandatory conversion of a convertible note that the Reporting Person acquired from the Issuer in a private placement in June 2025 at a conversion price of $8.3024, which is equal to 80% of the average closing price of the Issuer's shares of common stock on the Nasdaq Capital Market for the five trading days immediately preceding and including the conversion date of July 27, 2025.

Remarks:

On June 26, 2025, the Company implemented a 1-for-28 reverse stock split (the "Reverse Stock Split") of the Company's common stock. All amounts have been adjusted to give effect to the Reverse Stock Split.

	/s/ Jeffrey Meckler	07/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Aclaris Therapeutics (ACRS) announce in its 8-K?

The company disclosed it will discuss top-line Phase 2a results for ATI-2138 during a 29 Jul 2025 conference call and issued related exhibits.

Is the actual ATI-2138 Phase 2a data included in the filing?

No. The 8-K references a presentation (Ex. 99.1) and press release (Ex. 99.2); the filing itself contains no numerical results.

What is ATI-2138?

ATI-2138 is an investigational oral covalent ITK/JAK3 inhibitor being studied for moderate-to-severe atopic dermatitis.

Are the furnished materials considered "filed" with the SEC?

No. Under Reg FD, Items 7.01 and 8.01 are furnished, not filed, and are not subject to Exchange Act liability.

Will this 8-K affect Aclaris’s financial statements?

The filing contains no financial statements or guidance updates, so existing financials remain unchanged.